Compare Medtronic PLC (MDT) vs Prospect Capital Corporation (PSEC) Price & Performance

Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.

The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.

PSEC trades at $2.235, down 0.67% on the day, with a bearish technical signal and neutral oscillators. The stock shows a deeply discounted P/B ratio of 0.38 but alarming fundamentals, including a negative revenue of -$407M and a net income margin of -495.94% for 2025. Recent quarterly EPS has consistently beaten estimates, and the company maintains regular dividend payments. Analyst consensus is mixed, with 25% buy ratings but a majority hold recommendation.

The outlook for PSEC is highly speculative. The extreme discount to book value and high dividend yield present a potential value opportunity, but this is overshadowed by severe profitability issues and negative cash flow. Investment carries significant risk due to the company's inconsistent revenue history and bearish market sentiment, requiring careful consideration of the underlying asset quality.